E-4997 Erlotinib, Free Base, >99%

Synonyms : [CP-358774] [OSI-774] [Ro 50-8231]

Related Terms : [Tarceva]

  • Size
  • US $
  • £
  • ¥
  • 500 mg
  • 37
  • 34
  • 29
  • 5,800
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 48
  • 44
  • 37
  • 7,600
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 72
  • 67
  • 56
  • 11,400
  • Add to Cart Qty:
  • In stock
  • 5 g
  • 136
  • 126
  • 106
  • 21,500
  • Add to Cart Qty:
  • In stock
  • 10 g
  • 238
  • 221
  • 187
  • 37,600
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 32 Other Countries
  • M.W. 393.44
  • C22H23N3O4
  • [183321-74-6]
  • M.I. 14: 3672

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 10 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 5-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • More than 830 labs worldwide have purchased Erlotinib or its salt forms from LC Labs (either directly from us or from our many distributors, many of whom resell under their own labels).
  • This research compound is the free base form of erlotinib.  We also offer the hydrochloride salt form of erlotinib:  Cat. No.  E-4007 Erlotinib, Hydrochloride Salt.
  • Related CAS numbers: 248594-19-6 for erlotinib mesylate.
  • This erlotinib product is the free base, whose CAS number is given above. The CAS number of the hydrochloride salt is 183319-69-9.
  • Erlotinib (as the hydrochloride salt ) is the active ingredient in the drug product sold under the trade name Tarceva®. This drug has been approved in at least one country for use in patients with pancreatic cancer, non-small cell lung cancer and several other types of cancer. NOTE: THE ERLOTINIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT TARCEVA®, AND IS NOT FOR HUMAN USE.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.